- Policy
- How Samsung’s biosimilar became covered in the US
- by Lee, Hye-Kyung Sep 22, 2023 05:41am
- Language barriers, insufficient handling of administrative issues related to regulations and visas, difficulties in recruiting and managing local personnel, and lack of a network infrastructure were pointed to as barriers to the Korean pharmaceutical companies’ entry into the U.S. Entry into the U.S. market holds significance in the industr
- Policy
- Vabysmo·Evrysdi, listed as reimbursement
- by Lee, Tak-Sun Sep 22, 2023 05:41am
- It is reported that Vabysmo and Spinal Muscular Atrophy Evrysdi Dry Syrup 0.75mg/mL will be listed on the benefit in October. Additionally, the upper limit for 2 Jardiance items and 2 Ninlaro items is expected to be reduced due to PVA. It is reported that the upper limit price of pseudoephedrine ingredient preparations that have completed ne
- Policy
- Bioequivalence reevals speed up in line with drug price reev
- by Lee, Hye-Kyung Sep 21, 2023 05:24am
- With the number of items requiring equivalence tests expanded as such, the Ministry of Food and Drug Safety is also accelerating the reevaluation of those that were previously approved. In particular, it is said that the review is being further accelerated this year as its timing overlaps with the reevaluation of the insurance price ceiling amou
- Policy
- Pseudoephedrine price negotiations have been concluded
- by Lee, Tak-Sun Sep 21, 2023 05:24am
- Quick agreement reached after a week of negotiations, likely to be implemented in October It appears that the single agent for colds, Pseudoephedrine, will be subject to increased drug prices starting in October. There is news that drug price adjustment negotiations with the NHIS, which have been ongoing since last week, have been concluded
- Policy
- ‘Introduce a Korean Cancer Moonshot Plan for patients'
- by Lee, Jeong-Hwan Sep 21, 2023 05:24am
- It has been pointed out that Korea also needs a policy that can improve the quality of life of cancer patients by providing reasonable compensation for cancer treatment technologies such as robot-assisted surgery and advanced radiation therapy to improve the quality of life of cancer patients in Korea, like in the case of the U.S. Cancer Mo
- Policy
- Generics for Janumet competition begins in earnest in Oct.
- by Lee, Tak-Sun Sep 21, 2023 05:23am
- The diabetes treatment market is expected to remain active in October. This is because salt-modifying complex drugs that were not registered in September are hitting the market all at once. According to the industry on the 20th, generics of MSD's DPP-4 inhibitory diabetes combination drug 'Janumet and Janumet XR' will be listed in large numb
- Policy
- High-priced drugs need adjustment from the approval stage
- by Lee, Tak-Sun Sep 20, 2023 05:36am
- He also explained that he would conduct a pilot project to curb multi-drug prescriptions to reduce usage. Chairman Jeong made this announcement at a press conference for a health magazine held at a restaurant in Gwanghwamun, Seoul on the 15th. He said, “It is true that as income increases, prescriptions switch to more expensive drugs even i
- Policy
- The NHIS begins negotiations to increase the size of PSE
- by Lee, Tak-Sun Sep 20, 2023 05:36am
- The NHIS has started negotiations to adjust the drug price increase for the ingredient formulation of the nose cold medicine Pseudoephedrine (PSE), which is struggling with supply and demand. The deadline for this negotiation is 60 days, but it is said to be targeting an agreement this month. If this month's negotiations are signed, it is h
- Policy
- Reimbursement imminent for some anticancer drugs in KOR
- by Lee, Tak-Sun Sep 20, 2023 05:35am
- Jeperli Inj (dostarlimab, GSK) and Braftovi Cap 75mg (encorafenib, Ono), which passed the Drug Reimbursement Evaluation Committee meeting last month, are currently in drug price negotiations with the National Health Insurance Service. According to industry sources on the 19th, the National Health Insurance Service recently updated the li
- Policy
- MFDS starts review on phenylephrine after FDA advisory decis
- by Lee, Hye-Kyung Sep 19, 2023 05:42am
- With the Nonprescription Drug Advisory Committee (NDAC) concluding that the nasal decongestant ‘phenylephrine’ is not effective, Korea’s Ministry of Food and Drug Safety is also preparing to conduct its review. An MFDS official said, “We will decide on future measures after a comprehensive review, including discussion with experts,
